TITLE

Lantus

PUB. DATE
February 2011
SOURCE
Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the ongoing investigation conducted by the U.S. Food and Drug Administration (FDA) of the Lantus diabetes drug from Sanofi-Aventis US LLC.
ACCESSION #
58103696

 

Related Articles

  • FDA Clears Two Prostate Medications.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p57 

    The article reports that the U.S. Food and Drug Administration has cleared the new chemotherapy drug Jevtana for advanced prostate cancer from Sanofi-aventis.

  • Sanofi-Aventis wins FDA approval for tumor lysis syndrome drug.  // PharmaWatch: Cancer;Dec2009, Vol. 8 Issue 12, p13 

    The article presents information on the U.S. Food & Drug Administration's (FDA) approval for marketing of medicine Elitek developed by Sanofi-Aventis US LLC. The medicine helps in monitoring the plasma uric acid in the patients suffering from leukemia, lymphoma, and solid tumor malignancies. The...

  • Leukemia Update.  // PharmaWatch: Cancer;Jun2009, Vol. 8 Issue 6, p6 

    The article presents issues in the U.S. related to the disease Leukemia. The U.S. commercial rights to Oforta, an oral B-cell chronic lymphocytic leukemia drug, has been acquired by Sanofi-Aventis U.S. LLC from Antisoma PLC of Great Britain. The Food and Drug Administration (FDA) has accepted...

  • Tent Cards Create Flap.  // Pharmaceutical Representative;Dec2009, Vol. 39 Issue 12, p8 

    The article reports on the warning letter received by pharmaceutical company Sanofi-Aventis US LLC from the U.S. Food and Drug Administration (FDA) concerning the company's distribution of promotional card for its drug Uroxatral. It says that the card does not list risk information to caution...

  • Dronedarone: A New Therapeutic Alternative for Cardiac Arrhythmias. Upaganlawar, A.; Gandhi, H.; Balaraman, R. // Journal of Young Pharmacists;2010, Vol. 2 Issue 4, p430 

    The article discusses the negative therapeutic properties of dronedarone, a drug from Sanofi-Aventis US LLC, in the U.S. Dronedarone was approved by the U.S. Food and Drug Administration (FDA) on July 2, 2009 and is a therapeutic agent for cardiac arrhythmia. The author noted that the drug was a...

  • Trial watch: Novel antiarrhythmic agent shows promise in Phase III trial.  // Nature Reviews Drug Discovery;Apr2009, Vol. 8 Issue 4, p266 

    The article focuses on the study on Phase III ATHENA dronedarone trial that is used for treating atrial fibrillation. Accordingly, the dronedarone is a drug from the Sanofi-Aventis U.S. LLC that can be used to maintain sinus rhythm and manipulate ventricular rate on the reoccurrences of atrial...

  • News in brief.  // Nature Reviews Drug Discovery;Mar2011, Vol. 10 Issue 3, p165 

    The article offers drug news briefs in the U.S. The Food and Drug Administration (FDA) panelists have called for higher hurdles for accelerated drugs approvals in oncology. According to a study, the public sector has contributed to the discovery of 153 drugs over the past 40 years. A number of...

  • Sanofi, Novo Nordisk roll out new promos for pens. Arnold, Matthew // Medical Marketing & Media;Jun2010, Vol. 45 Issue 6, p22 

    The article reports on the consumer campaign of Sanofi-Aventis US LLC for Lantus SoloStar pen aiming to make the people understand better about insulin for type 2 diabetes in the U.S.

  • American Diabetes Association.  // BioWorld Today;6/9/2009, Vol. 20 Issue 109, p10 

    The article discusses the results of a study by Sanofi-Aventis U.S. which examined that safety and effectiveness of its Lantus or insulin glargine compared to neutral protemine Hagedorn (NPH) insulin in older adults with Type II diabetes. After 24 weeks of treatment, no significant difference...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics